Search

Your search keyword '"Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units"' showing total 10 results
Start Over Descriptor "Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units"
10 results on '"Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units"'

1. Abbott to buy Solvay drug unit for $7 billion: deal opens avenues to emerging markets while adding heart and hormone treatments as well as a flu vaccine

Author

Whalen, Jeanne, Cimilluca, Dana, and McCracken, Jeffrey

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company acquisition/merger, Banking, finance and accounting industries, Business, Business, international
Abstract

Abbott Laboratories has agreed to buy Solvay S.A.'s pharmaceutical unit for about 4.8 billion euro in cash. Abbott will also pay up to 300 million euro between 2011 and 2013 if the unit reaches certain targets. The acquisition gives Abbott access to emerging markets where it has limited presence, and control of a flu vaccine, and cardiovascular and hormone treatments.

Published
2009

2. Solvay will seek buyers for drug division

Author

Whalen, Jeanne and Cimilluca, Dana

Subjects
Solvay S.A. (Brussels, Belgium) -- Planning, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Company sales and earnings, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Securities, Solvay Pharmaceuticals B.V. -- Planning, Solvay Pharmaceuticals B.V. -- Mergers, acquisitions and divestments, Solvay Pharmaceuticals B.V. -- Company sales and earnings, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company business planning, Company acquisition/merger, Company earnings/profit, Company securities, Banking, finance and accounting industries, Business, Business, international
Abstract

Belgian conglomerate Solvay S.A. is looking to sell its pharmaceuticals division which had 2.7 billion in sales and accounted for 28% of the company's total revenue in 2008. Solvay's shares rose 9% to 57.50 euro in Wednesday trading.

Published
2009

3. Rhodia Polyamide & Intermediates, a member of the Solvay group, says it has developed an extended range of novel intermediates exploiting upstream [C.sub.6] chemistry know-how in the polyamide 6.6 manufacturing chain

Subjects
Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Pesticides industry -- Subsidiaries, divisions and units, Polymer industry -- Subsidiaries, divisions and units -- Product development, Herbicides -- Subsidiaries, divisions and units, Chemical industry -- Subsidiaries, divisions and units, Business, Chemicals, plastics and rubber industries, Chemistry
Abstract

Rhodia Polyamide & Intermediates, a member of the Solvay group, says it has developed an extended range of novel intermediates exploiting upstream [C.sub.6] chemistry know-how in the polyamide 6.6 manufacturing [...]

Published
2012

4. ICIG adds two more European sites

Subjects
AstraZeneca PLC -- Mergers, acquisitions and divestments, AstraZeneca PLC -- Buildings and facilities, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Investment companies -- Mergers, acquisitions and divestments, Chemical industry -- Mergers, acquisitions and divestments, Chemical industry -- Subsidiaries, divisions and units, Chemical industry -- Buildings and facilities, Herbicides -- Mergers, acquisitions and divestments, Herbicides -- Subsidiaries, divisions and units, Herbicides -- Buildings and facilities, Pesticides industry -- Mergers, acquisitions and divestments, Pesticides industry -- Subsidiaries, divisions and units, Pesticides industry -- Buildings and facilities, Company acquisition/merger, Business, Chemicals, plastics and rubber industries
Abstract

Private investment company International Chemical Investors Group (ICIG) has bought two new European sites to add to its growing portfolio of medium-sized chemical businesses. ICIG has bought Synkem from Solvay and an AstraZeneca site in Germany. ICIG's track record of acquisition deals are also discussed.

Published
2007

5. Solvex-Solvay, a subsidiary of Belgian chemicals concern Solvay, is doubling capacity at its perfluoropolyether (PFPE) production site in Spinetti Marengo, Italy, with completion scheduled for 2008

Author

Eisberg, Neil

Subjects
Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Production management, Chemical industry -- Subsidiaries, divisions and units, Chemical industry -- Production management, Herbicides -- Subsidiaries, divisions and units, Herbicides -- Production management, Pesticides industry -- Subsidiaries, divisions and units, Pesticides industry -- Production management, Glycol ethers -- Production management, Business, Chemicals, plastics and rubber industries
Published
2007

6. Friendly Girindus bid

Subjects
Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Organization formation, Chemical industry -- Organization formation, Chemical industry -- Subsidiaries, divisions and units, Herbicides -- Organization formation, Herbicides -- Subsidiaries, divisions and units, Pesticides industry -- Organization formation, Pesticides industry -- Subsidiaries, divisions and units, Business, Chemicals, plastics and rubber industries
Published
2005

7. Abbott to cut 3,000 jobs in aftermath

Author

Loftus, Peter

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Human resource management, Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments, Abbott Laboratories (Abbott Park, Illinois) -- Reorganization and restructuring, Abbott Laboratories (Abbott Park, Illinois) -- Finance, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Chemical industry -- Subsidiaries, divisions and units, Chemical industry -- Mergers, acquisitions and divestments, Herbicides -- Subsidiaries, divisions and units, Herbicides -- Mergers, acquisitions and divestments, Pesticides industry -- Subsidiaries, divisions and units, Pesticides industry -- Mergers, acquisitions and divestments, Costs, Industrial -- Control, Pharmaceutical industry -- Human resource management, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Reorganization and restructuring, Pharmaceutical industry -- Finance, Layoffs -- Planning, Acquisitions and mergers -- Finance, Company personnel management, Company acquisition/merger, Company restructuring/company reorganization, Company organization, Company financing, Company business planning, Layoff, News, opinion and commentary
Published
2010

8. U.S. drug companies chase vaccines

Author

Rockoff, Jonathan D. and Loftus, Peter

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments, CSL Ltd. (Parkville, Victoria) -- Licensing agreements, CSL Ltd. (Parkville, Victoria) -- Mergers, acquisitions and divestments, Crucell N.V. -- Mergers, acquisitions and divestments, Johnson & Johnson -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Marketing, Merck & Company Inc. -- Licensing agreements, Pfizer Inc. -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Biological products industry -- Licensing agreements, Biological products industry -- Mergers, acquisitions and divestments, Biotechnology industry -- Mergers, acquisitions and divestments, Chemical industry -- Mergers, acquisitions and divestments, Chemical industry -- Subsidiaries, divisions and units, Herbicides -- Mergers, acquisitions and divestments, Herbicides -- Subsidiaries, divisions and units, Pesticides industry -- Mergers, acquisitions and divestments, Pesticides industry -- Subsidiaries, divisions and units, Pharmaceutical industry -- Forecasts and trends, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Marketing, Pharmaceutical industry -- Intellectual property, Influenza vaccines -- Licensing agreements, Influenza vaccines -- Intellectual property, Influenza vaccines -- Product development, Influenza vaccines -- Marketing, Company licensing agreement, Company acquisition/merger, Company marketing practices, Market trend/market analysis, News, opinion and commentary
Published
2009

9. Abbott to buy Solvay drug unit for $7 billion; deal opens avenues to emerging markets while adding heart and hormone treatments as well as a flu vaccine

Author

Whalen, Jeanne, Cimilluca, Dana, and McCracken, Jeffrey

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Planning, Chemical industry -- Subsidiaries, divisions and units, Chemical industry -- Mergers, acquisitions and divestments, Herbicides -- Subsidiaries, divisions and units, Herbicides -- Mergers, acquisitions and divestments, Pesticides industry -- Subsidiaries, divisions and units, Pesticides industry -- Mergers, acquisitions and divestments, Drugs -- Marketing, Pharmaceutical industry -- Mergers, acquisitions and divestments, Subsidiary corporations -- Mergers, acquisitions and divestments, Vaccines -- Marketing, Company acquisition/merger, Company business planning, Company marketing practices, News, opinion and commentary
Published
2009

10. Abbott joins bidding for Solvay drug unit

Author

Whalen, Jeanne, McCracken, Jeffrey, and Cimilluca, Dana

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Negotiation, mediation and arbitration, Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Negotiation, mediation and arbitration, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, UCB S.A. -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Negotiation, mediation and arbitration, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Subsidiaries, divisions and units, Tender offers (Securities) -- Analysis, Chemical industry -- Negotiation, mediation and arbitration, Chemical industry -- Mergers, acquisitions and divestments, Herbicides -- Negotiation, mediation and arbitration, Herbicides -- Mergers, acquisitions and divestments, Pesticides industry -- Negotiation, mediation and arbitration, Pesticides industry -- Mergers, acquisitions and divestments, Company acquisition/merger, News, opinion and commentary
Abstract

A deal possibly worth from US$5.9 billion to $7.4 billion is in the works as Abbott Laboratories makes an offer for the pharmaceutical unit of Solvay S.A., the Belgian conglomerate corporation. Another Belgian company, UCB SA , is also thinking of bidding.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results